Progenics Pharmaceuticals

A Covid-19 threat to business acquisitions

20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.

October 03, 2019

Lantheus shareholders take short-term view of Progenics deal

July 20, 2018

Upcoming events – FDA decision for Progenics and Allergy comes out of hiding

Progenics hopes to secure US approval for Azedra, while Allergy Therapeutics awaits phase III data with its birch vaccine.

January 09, 2013

Sarepta joins the big league as best-performing 2012 share

November 12, 2012

Nektar and Astra’s naloxegol set for silver medal after trial success

October 10, 2012

Wockardt and Arena lead small-cap gainers through nine months

September 07, 2012

Event – Naloxegol set to provide a Kodiac moment for Nektar

July 31, 2012

Progenics and Salix suffer as FDA blocks constipation drug

July 20, 2012

Key regulatory events for the next six months

December 21, 2011

Progenics' Relistor moving nicely through trial success

February 08, 2011

Salix takes Relistor's commercial reins from Pfizer

Load More